International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed | PAR 21 104

Opportunity Information: Apply for PAR 21 104

The International Research Scientist Development Award (IRSDA) (K01) is an NIH career development grant designed to help advanced postdoctoral researchers and newly appointed junior faculty in the United States build a long-term, independent research career in global health. The core idea is to provide substantial protected time and support for an intensive, mentored research experience based in a low- or middle-income country (LMIC), using the World Bank country classifications (low-income, lower-middle-income, and upper-middle-income). The award is meant to span three to five years, giving recipients enough runway to deepen their expertise, develop strong international collaborations, and generate the track record needed to compete successfully for independent research funding later on.

This opportunity targets candidates who are already beyond the earliest training stage and are ready for focused career acceleration. Applicants must be at least two years past the conferral of their doctoral degree and must be either advanced postdoctoral U.S. research scientists or recently appointed U.S. junior faculty. The program is open to people from any health-related discipline, reflecting NIH's broad view of what contributes to global health, including biomedical, clinical (non-independent clinical trial), behavioral, public health, implementation science, health systems, and other relevant research areas, as long as the proposed work is aligned with real health priorities in the LMIC setting.

A defining feature of the IRSDA is its structured mentorship model and the expectation of meaningful engagement in the LMIC environment. Applicants are expected to propose a career development plan and a specific research project to be carried out with guidance from both LMIC-based and U.S.-based mentors. This dual-mentorship structure is intended to ensure that the work is scientifically rigorous, feasible, and grounded in local context, while also supporting the candidate's progression toward independence within the U.S. research funding ecosystem. The research should be relevant to the host country's needs rather than being a project that could be done anywhere with only minimal local involvement. In practice, competitive applications typically emphasize strong partnerships, well-justified training goals, and a plan for building skills and outputs that clearly lead toward future independent grants.

The FOA is labeled "Independent Clinical Trial Not Allowed," which signals an important boundary about the type of research that can be supported. While applicants may be able to work with clinical data or engage in human subjects research depending on NIH rules and the specific proposal, the candidate is not permitted to lead an independent clinical trial as part of this K01. The intent is career development through mentored research and training, not serving as the principal driver of a standalone clinical trial.

Eligibility to apply is limited to U.S. organizations. Eligible applicant organizations include public and state-controlled institutions of higher education, private institutions of higher education, and other qualifying U.S. entities. The announcement explicitly notes inclusivity for a range of institution types, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs). At the same time, non-U.S. institutions cannot apply as the primary applicant organization, and non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components, as NIH defines them in its Grants Policy Statement, are allowed, which aligns with the program's central requirement of conducting intensive work in an LMIC.

From an administrative standpoint, this is a discretionary grant mechanism administered by the National Institutes of Health. The funding opportunity number is PAR-21-104, and it falls under the education and health activity category, with CFDA numbers 93.398 and 93.989. The source data lists an original closing date of 2023-03-08. The overall message of the program is straightforward: NIH is investing in promising U.S.-based early-career scientists to gain deep, mentored global health research experience in LMIC settings and to emerge ready to sustain an independently funded research program centered on global health priorities.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.398, 93.989.
• This funding opportunity was created on 2021-01-04.
• Applicants must submit their applications by 2023-03-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Public and State controlled institutions of higher education, Private institutions of higher education, Others.

Apply for PAR 21 104

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: